Bio-Works has received two orders worth a total of SEK 1.1 million from an American customer who manufactures therapeutic peptides. The buyer has confirmed the use is peptide manufacturing. One order has already been delivered and the other was confirmed late yesterday for delivery before the turn of the year.
Jonathan Royce, CEO of Bio-Works:
"We are pleased that our previous investments in the US market are beginning to pay off. The fact that our products are used in several large-scale processes is proof that Bio-Works' products are competitive and that they lead to improved production efficiency for our customers. We see several opportunities ahead to expand our sales in the peptide manufacturing market. ”
Bio-Works has seen a clear escalation of sales in 2020. After Q3, the order book had already passed the total sales achieved in 2019. Bio-Works has 59 customer projects that are in the scale-up phase. Each individual customer project that is in industrial production can be worth up to SEK 10 million in annual revenue for Bio-Works.
In peptide purification, it is Bio-Works so-called ion exchangers that drive growth. WorkBeads™ S and WorkBeads Q are third generation, unique agarose resins, specially developed for the commercial production of valuable large scale therapeutic molecules (such as peptides). Bio-Works has shown that WorkBeads products provide higher capacity and higher purity in peptide purification, compared to products from competitors.
For more information please visit Bio-Works homepage, www.bio-works,com, or contact Jonathan Royce, CEO, e-mail: jonathan.royce@bio-works.com, telephone: +46 70 143 41 43.
Bio-Works designs, develops, manufactures and supplies innovative leading edge agarose products for chromatographic separation of proteins, peptides and other biomolecules. The company is staffed by people with long experience in the biotech industry and particularly with protein separation media. Bio-Works’ agarose-based high performance products are used for purification in the life science research phase as well as the commercial production of biopharmaceuticals and diagnostic products in large scale. The products are sold globally through our own organization and via distributors. Bio-Works facilities are located in the Uppsala Business Park Uppsala, Sweden. Company processes and a Quality Management System follow the standards of ISO 9001:2008. The Bio-Works’ share is traded on Nasdaq First North in Stockholm. FNCA Sweden AB is the Certified Adviser.